Rituximab for treatment of intermediate and aggressive B-cell non-Hodgkin's lymphomas

BlueCross BlueShield Association
Record ID 32003000762
Authors' objectives:

In a prior Technology Evaluation Center (TEC) Assessment (Vol. 16, No. 7; 2001), the Blue Cross and Blue Shield Association Medical Advisory Panel concluded that use of rituximab for patients with intermediate grade or aggressive non-Hodgkins lymphoma (NHL) did not meet the TEC criteria. The earlier Assessments Review of Evidence summarized preliminary results from a randomized controlled trial that compared combination chemotherapy alone to the same combination plus rituximab for patients with diffuse large B-cell lymphoma (the most common type of intermediate/aggressive NHL). At that time, however, these results were available only in meeting abstracts and had not yet been published in a peer-reviewed journal. This randomized trial recently was published in full. Consequently, the objective of this Assessment is to update the Assessment conclusions on the use of rituximab for patients with intermediate or aggressive B-cell NHL.

Authors' methods: Systematic review
Project Status: Completed
Year Published: 2002
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Lymphoma, Non-Hodgkin
Organisation Name: BlueCross BlueShield Association
Contact Address: BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name: tec@bcbsa.com
Contact Email: tec@bcbsa.com
Copyright: BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.